Join the Wegovy group to help and get support from people like you.
Wegovy News (Page 4)
More U.S. Teens Are Now Taking Wegovy for Weight Loss
THURSDAY, June 5, 2025 — More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment. But experts say access is still limited, and mo...
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 – For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with...
Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers
WEDNESDAY, May 28, 2025 — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new study says. People taking a ...
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 – Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in confirmatory trials, with a...
FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs
FRIDAY, May 23, 2025 — A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on. The U.S. Food and Drug A...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 – For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric...
GLP-1 Drugs Appear To Lower Cancer Risk
MONDAY, May 19, 2025 — Cutting-edge GLP-1 weight-loss drugs appear to help lower cancer risk even beyond the benefits from dropping excess pounds, a new study says. First-generation GLP-1 drugs like l...
Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills
FRIDAY, May 16, 2025 — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal ...
More U.S. Teens Getting Weight-Loss Surgery
WEDNESDAY, May 14, 2025 — More U.S. teenagers are getting weight-loss surgery, despite the discovery of new drugs like Ozempic/Wegovy that help people drop pounds surgery-free, a new study says. W...
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
TUESDAY, May 13, 2025 — Cutting-edge weight-loss drugs like Ozempic/Wegovy can cut alcohol intake dramatically in a short amount of time, a new study says. People taking semaglutide or liraglutide r...
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
TUESDAY, May 13, 2025 — Cutting-edge weight-loss drugs like Ozempic/Wegovy can cut alcohol intake dramatically in a short amount of time, a new study says. People taking semaglutide or liraglutide r...
GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity
MONDAY, May 12, 2025 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and...
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
MONDAY, May 12, 2025 — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The study — published May 11 in th...
Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
FRIDAY, May 2, 2025 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study...
Ozempic Can Treat Fatty Liver Disease
THURSDAY, May 1, 2025 – The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has found. Nearly twice as many people taking semaglutide...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Nonalcoholic Fatty Liver Disease